A tighter archive for life-science signals.
Search once, then narrow by source or topic.
The Data Multiplier Effect: When Expertise, Monitoring, Systems, and AI Align
The Data Multiplier Effect: When Expertise, Monitoring, Systems, and AI Align
UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge
UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Chutes & Ladders—Moderna CMO steps down in leadership mix-up
Chutes & Ladders—Moderna CMO steps down in leadership mix-up
Qiagen 'open for discussion' on shareholder value, but CEO stays mum on takeover talk
Qiagen 'open for discussion' on shareholder value, but CEO stays mum on takeover talk
Medtronic hit with $382M antitrust ruling over surgical device monopoly
Medtronic hit with $382M antitrust ruling over surgical device monopoly
Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M
Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M
NICE greenlights Abbott's cardiac sensor implant for NHS
NICE greenlights Abbott's cardiac sensor implant for NHS
Astellas tops expectations as Vyloy sales surge outshines trial setback
Astellas tops expectations as Vyloy sales surge outshines trial setback
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA
Flagship-founded antibody biotech Generate is latest to mull IPO
Flagship-founded antibody biotech Generate is latest to mull IPO
A cut above: Veradermics locks in $256M IPO and shares spike
A cut above: Veradermics locks in $256M IPO and shares spike
Angitia raises $130M to challenge Amgen with bone-building bispecifics
Angitia raises $130M to challenge Amgen with bone-building bispecifics
GE HealthCare posts higher full-year revenues amid turbulent tariff backdrop
GE HealthCare posts higher full-year revenues amid turbulent tariff backdrop
Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024
Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024
Quell halts liver transplant Treg trial to focus on preclinical 'chill not kill' candidate
Quell halts liver transplant Treg trial to focus on preclinical 'chill not kill' candidate
FDA’s rare pediatric disease voucher program revived by 2026 government funding bill
FDA’s rare pediatric disease voucher program revived by 2026 government funding bill
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page